MitoQ Treatment of Claudication: Myofiber and Micro-vessel Pathology

Description

In our research, we are delving into whether taking MitoQ for six months can improve the symptoms and function of people diagnosed with peripheral artery disease, especially those who suffer from leg pain while walking, known as intermittent claudication. We will be checking if MitoQ helps people with claudication walk better, be more active every day, feel better about their lives, and if it enhances the health of their leg muscles.

Conditions

Peripheral Arterial Disease

Study Overview

Study Details

Study overview

In our research, we are delving into whether taking MitoQ for six months can improve the symptoms and function of people diagnosed with peripheral artery disease, especially those who suffer from leg pain while walking, known as intermittent claudication. We will be checking if MitoQ helps people with claudication walk better, be more active every day, feel better about their lives, and if it enhances the health of their leg muscles.

MitoQ Treatment of Claudication: Myofiber and Micro-vessel Pathology

MitoQ Treatment of Claudication: Myofiber and Micro-vessel Pathology

Condition
Peripheral Arterial Disease
Intervention / Treatment

-

Contacts and Locations

Omaha

VA Medical Center, Omaha, Nebraska, United States, 68105

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. a positive history of chronic claudication
  • 2. exercise-limiting claudication established by history and direct observation during a screening walking test administered by the evaluating vascular surgeon
  • 3. documented lower extremity arterial occlusive disease based on ankle/brachial index measurements and/or arterial imaging
  • 4. stable blood pressure, lipid and diabetes regimens and risk factor control for 6 weeks.
  • 1. rest pain or tissue loss due to PAD (Fontaine stage III and IV)
  • 2. acute lower extremity ischemic event
  • 3. walking capacity significantly and primarily limited by conditions other than claudication including leg (joint/musculoskeletal, neurologic) and systemic (heart, lung disease) pathology.

Ages Eligible for Study

21 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Nebraska,

Iraklis Pipinos, MD, PRINCIPAL_INVESTIGATOR, University of Nebraska

Study Record Dates

2027-06